Half Title Page.
Preface to the Fourth Edition.
2: The Bone Organ System: Form and Function.
3: The Nature of Osteoporosis.
4: Reflections on Osteoporosis.
5: Reflections on Development of Concepts of Intercellular Communication in Bone.
6: Osteo-Odyssey: A Memoir.
7: Cellular, Molecular, and Developmental Biology of Bone.
8: Development of the Skeleton.
9: The Skeletal Stem Cell.
10: Osteoclast Biology.
11: Osteoblast Biology.
12: Osteocyte Biology.
13: The Regulatory Role of Matrix Proteins in Mineralization of Bone.
14: Skeletal Hormones and Regulatory Factors.
15: Parathyroid Hormone and Parathyroid Hormone-Related Protein.
16: Vitamin D: Biology, Actions, and Clinical Implications.
17: Regulation of Bone Cell Function by Estrogens.
18: Androgens and Skeletal Biology: Basic Mechanisms.
20: Skeletal Growth Factors.
21: WNT Signaling in Skeletal Homeostasis and Diseases.
22: Skeletal Structure and Biomechanics.
23: The Mechanical Behavior of Bone.
24: Cellular and Molecular Mechanotransduction in Bone.
25: Adaptation of Skeletal Structure to Mechanical Loading.
26: Biomechanics of Hip and Vertebral Fractures.
27: Prevention of Osteoporosis by Physical Signals: Defining a Potential Role for Nondrug Strategies in the Treatment of Musculoskeletal Injury and Disease.
28: Epidemiology of Osteoporosis.
29: Epidemiologic Methods in Studies of Osteoporosis.
30: Genetic Determinants of Osteoporosis.
31: Race, Ethnicity, and Osteoporosis.
32: Geographic Variability in Hip and Vertebral Fractures.
33: Nutrition and Risk for Osteoporosis.
34: Physical Activity and Exercise in the Maintenance of the Adult Skeleton and the Prevention of Osteoporotic Fractures.
35: Premenopausal Reproductive and Hormonal Characteristics and the Risk for Osteoporosis.
36: Clinical and Epidemiological Studies: Skeletal Changes across Menopause.
37: Osteoporosis in Men: Epidemiology, Pathophysiology, and Clinical Characterization.
38: Falls as Risk Factors for Fracture.
39: Nonskeletal Risk Factors for Osteoporosis and Fractures.
40: Outcomes Following Osteoporotic Fractures.
41: General Pathophysiology of Osteoporosis.
42: Skeletal Heterogeneity and the Purposes of Bone Remodeling: Implications for the Understanding of Osteoporosis.
43: On the Evolution and Contemporary Roles of Bone Remodeling.
44: Cytokines and the Pathogenesis of Osteoporosis.
45: Animal Models for Osteoporosis.
46: Bone and Fat.
47: Bone Mineral Acquisition in Utero and During Infancy and Childhood.
48: Bone Acquisition in Adolescence.
Half Title Page.
1: General Pathophysiology of Osteoporosis.
2: Osteoporosis in Childhood and Adolescence.
3: Osteoporosis Associated with Pregnancy.
4: Osteoporosis in Premenopausal Women.
5: Estrogen Deficiency, Postmenopausal Osteoporosis, and Age-Related Bone Loss.
6: Spectrum of Secondary Osteoporosis.
7: Immobilization Osteoporosis.
8: Osteoporosis Associated with Illnesses and Medications.
9: Glucocorticoid-Induced Osteoporosis.
10: Anticonvulsant-Related Bone Disease.
11: Thyroid Hormone and the Skeleton.
12: The Skeletal Actions of Parathyroid Hormone in Primary Hyperparathyroidism and in Osteoporosis.
13: Osteogenesis Imperfecta and Other Defects of Bone Development as Occasional Causes of Adult Osteoporosis.
14: HIV and Osteoporosis.
15: Obesity, Diabetes, and Fractures.
16: Osteoporosis in Organ Transplant Patients.
17: Osteoporosis Associated with Rheumatologic Disorders.
18: Osteoporosis Associated with Chronic Kidney Disease.
19: Oral Bone Loss and Systemic Osteoporosis: Weighing the Risk Benefit Ratio of Treatment.
20: Cancer and Osteoporosis.
21: Cancer Treatment-Induced Bone Loss in Patients with Breast Cancer: Pathophysiology and Clinical Perspectives.
22: Pathophysiology—Prostate Cancer.
23: Mechanisms of Bone Destruction in Myeloma.
24: Diagnosis and Evaluation.
25: Evaluation of the Patient at Risk for Osteoporosis.
26: Imaging of Osteoporosis.
27: Osteoporosis: Who Should be Treated? Who Should be Screened?.
28: Clinical Use of Bone Densitometry.
29: Biochemical Markers of Bone Turnover in Osteoporosis.
30: Fracture Risk Assessment: The Development and Application of FRAX®.
31: Patient Management.
32: Orthopedic Aspects of Osteoporosis.
33: Falls Prevention Interventions.
34: Physical Therapy, Physical Modalities, and Exercise Regimens in the Management of Osteoporosis.
35: Calcium in the Treatment of Osteoporosis.
36: Vitamin D and its Metabolites and Analogs in the Management of Osteoporosis.
37: Alternative Therapy through Nutrients and Nutraceuticals.
39: Design Considerations for Clinical Investigations of Osteoporosis.
40: Lessons from Bone Histomorphometry on the Mechanisms of Action of Osteoporosis Drugs.
41: Estrogen and Estrogen Analogs for Prevention and Treatment of Osteoporosis.
43: Calcitonin in Osteoporosis.
44: Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis.
45: Osteonecrosis of the Jaw and Atypical Femoral Fractures.
46: Condition Critical: Compliance and Persistence with Osteoporosis Medications.
47: Denosumab for the Treatment of Osteoporosis.
48: Strontium Ranelate in the Prevention of Osteoporotic Fractures.
49: Parathyroid Hormone Treatment for Osteoporosis.
50: New Approaches to Osteoporosis Therapeutics.
51: The Past, Present, and Uncertain Future of Therapeutic Innovation in Osteoporosis.